Sparteine oxidation in patients with early- and late-onset of Parkinson’s disease
We studied the oxidation of sparteine in 36 patients with early onset (onset of age <50 years) and 36 patients with late onset (onset of age ⩾50 years) of Parkinson’s disease. The results were compared with those obtained from 84 healthy volunteers. Although no poor metabolizer was found in the patients with Parkinson’s disease, there was an inverse and significant (P < 0.01) relationship between the onset of age and log metabolic ratio (MR) of sparteine (Spearman’s rs = -0.431). The mean (±S.D.) MR value (1.52 ± 1.40) of the patients with early onset was significantly (P < 0.01) higher than, whereas that (0.81 ±0.99) of the patients with late onset was not significantly different from, that (0.62 ±0.62) of the control subjects with extensive metabolizer phenotype. The mean greater MR value found in the patients with early onset of Parkinson’s disease was derived mainly from the more frequency of patients with relatively greater MR value for phenotyping extensive metabolizers (MR > 1.5). These findings indicate that the oxidative capacity of sparteine is not defective but reduced in some patients with an earlier onset of Parkinson’s disease, possibly implying that the decreased activity of cytochrome P-450 responsible for the oxidation of sparteine would be a factor to accelerate the onset of the Parkinson’s disease.
KeywordsLate Onset Metabolic Ratio Antihistamine Drug Polymorphic Oxidation Sparteine Oxidation
Unable to display preview. Download preview PDF.
- Barbeau A, Cloutier T, Roy M, Plasse L, Paris S, Poirier J (1985) Ecogenetics of Parkinson’s disease: 4-hydroxylation of debrisoquine. Lancet ii: 1213–1216Google Scholar
- Gudjonsson O, Sanz E, Alvan G, Aquilonius S-M, Reviriego J (1989) Poor hydroxylator phenotypes of debrisoquine and S-mephenytoin are not over-represented in a group of patients with Parkinson’s disease. Br J Pharmacol 30: 301–302Google Scholar
- Langston JW, Irwin I (1986) MPTP: current concepts and controversies. Clin Neuro pharmacol 9: 487–507Google Scholar
- Marsden CD (1990) Parkinson’s disease. Lancet i: 948–952Google Scholar
- Ohta S, Tachikawa O, Makino Y, Tasaki Y, Hirobe M (1990) Metabolism and brain accumulation of tetrahydroisoquinoline (TIQ). A possible parkinsonism inducing substance, in an animal model of a poor debrisoquine metabolizer. Life Sci 46: 599–606Google Scholar
- Poirier J, Roy M, Campanella G, Cloutier T, Paris S (1987) Debrisoquine metabolism in Parkinsonian patients treated with antihistamine drugs. Lancet ii: 386Google Scholar
- Yokochi M, Narabayashi H (1981) Clinical characteristics of juvenile parkinsonism. In: Rose FC, Capildeo R (eds) Research progress in Parkinson’s disease. Pitman Medical, Tunbridge Wells, Kent, pp 35–39Google Scholar